ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

ProQR Therapeutics NV

03/11/2023 17:26

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Leiden Zuid-holland-based  company is expected to
report  a
246.9% increase in revenue to €3.316 million from €956 thousand
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $4.75​, above​ its last closing price
of $1.18. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.11      -0.10     Beat    10
 Mar. 31 2023  -0.09       -0.12      -0.11     Beat    6.5
 Dec. 31 2022  -0.17       -0.18      -0.16     Beat    10.4​
 Sep. 30 2022  -0.19       -0.21      -0.34     Missed  -61.5
 ​​Jun.        -0.22       -0.22      -0.21     Beat    2.7
 30 2022                                                
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15.1​
 Dec. 31 2021  -0.18       -0.19      -0.26     Missed  -40
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3
 This summary was machine generated November 3 at 17:26 GMT.  All
figures in euros  unless otherwise stated